For research use only. Not for therapeutic Use.
Zelasudil is a Rho-associated (ROCK) kinase inhibitor. Zelasudil has a ROCK2 binding affinity[1][2].
| Catalog Number | I041959 |
| CAS Number | 2365193-22-0 |
| Synonyms | 4-[5-[(4-cyclopropyl-1H-indazol-5-yl)amino]-1-methyl-1,2,4-triazol-3-yl]-N-(2,2-difluoroethyl)benzamide |
| Molecular Formula | C22H21F2N7O |
| Purity | ≥95% |
| InChI | InChI=1S/C22H21F2N7O/c1-31-22(27-17-9-8-16-15(10-26-29-16)19(17)12-2-3-12)28-20(30-31)13-4-6-14(7-5-13)21(32)25-11-18(23)24/h4-10,12,18H,2-3,11H2,1H3,(H,25,32)(H,26,29)(H,27,28,30) |
| InChIKey | HSZPZEGJQCFGDE-UHFFFAOYSA-N |
| SMILES | CN1C(=NC(=N1)C2=CC=C(C=C2)C(=O)NCC(F)F)NC3=C(C4=C(C=C3)NN=C4)C5CC5 |
| Reference | [1]. Lee E, et al. Selective ROCK2 inhibition for treatment of edema and associated conditions: World Intellectual Property Organization, WO2022169946. 2022-08-11. [2]. WHO Drug Information-World Health Organization (WHO). |
